Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

1.750 -0.080 (-4.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Robbins LLP Reminds IOVA Stockholders That a Class Action Lawsuit was Filed Against Iovance Biotherapeutics, Inc. Alleging the Company Misled Investors Regarding its Business Prospects
From Robbins LLP
Via GlobeNewswire
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
From SkyMedia, LLC
Via GlobeNewswire
IOVA Investors Have the Opportunity to Lead the Iovance Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
From Pomerantz LLP
Via GlobeNewswire
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
From Kahn Swick & Foti, LLC
Via GlobeNewswire
Kaplan Fox Alerts Investors of Iovance Biotherapeutics, Inc. (IOVA) to the Lead Plaintiff Deadline on July 14, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Kaplan Fox Alerts Investors of Iovance Biotherapeutics, Inc. (IOVA) to the Lead Plaintiff Deadline on July 14, 2025
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
From Pomerantz LLP
Via GlobeNewswire
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
From SkyMedia, LLC
Via GlobeNewswire
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
From The Rosen Law Firm PA
Via GlobeNewswire
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Topics Economy Law Enforcement
Exposures Economy Legal Product Safety
FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Continues Lead Plaintiff Search for Iovance Biotherapeutics, Inc. (IOVA) Securities Fraud Class Action
From Kahn Swick & Foti, LLC
Via GlobeNewswire
Down More Than 75% This Year, Should Investors Throw in the Towel on Iovance Biotherapeutics Stock?
Via The Motley Fool
Deadline Approaching: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
IOVA BREAKING NEWS: Iovance Biotherapeutics, Inc. Stock Plummets 44% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:IOVA)
From Bleichmar Fonti & Auld LLP
Via Business Wire
Law Offices of Frank R. Cruz Encourages Iovance Biotherapeutics, Inc. (IOVA) Investors To Inquire About Securities Fraud Class Action
From The Law Offices of Frank R. Cruz
Via Business Wire
Deadline Alert: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
From Glancy Prongay & Murray LLP
Via Business Wire
Kaplan Fox Encourages Investors of Iovance Biotherapeuitcs, Inc. (IOVA) to Contact the Firm Before Lead Plaintiff Deadline on July 14, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Kaplan Fox Encourages Investors of Iovance Biotherapeuitcs, Inc. (IOVA) to Contact the Firm Before Lead Plaintiff Deadline on July 14, 2025
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
From Pomerantz LLP
Via GlobeNewswire
IOVA Investors Have the Opportunity to Lead the Iovance Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
Kaplan Fox Alerts Investors of Iovance Biotherapeutics, Inc. (IOVA) to a Securities Class Action Deadline on July 14, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Kaplan Fox Alerts Investors of Iovance Biotherapeutics, Inc. (IOVA) to a Securities Class Action Deadline on July 14, 2025
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues Lead Plaintiff Search for Iovance Biotherapeutics, Inc. (IOVA) Securities Fraud Class Action
From Kahn Swick & Foti, LLC
Via Business Wire
IOVANCE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Why Iovance Biotherapeutics Tumbled by Nearly 6% Today
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.